Lutathera safety under the microscope: 1,000+ patients monitored Long-Term

NCT ID NCT03691064

Ongoing Knowledge-focused Sponsor: Advanced Accelerator Applications Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Phoenix, Arizona, 85006, United States
Novartis Investigative site

Clichy, France
Novartis Investigative site

Lyon, France
Novartis Investigative site

Villejuif, France
Novartis Investigative site

Coimbra, Coimbra District, 3000-075, Portugal
Novartis Investigative site

Santiago de Compostela, La Corunya, 15706, Spain
Novartis Investigative site

Majadahonda, Madrid, 28222, Spain
Novartis Investigative site

Birmingham, B152WB, United Kingdom
Novartis Investigative site

Cambridge, CB2 0QC, United Kingdom
Novartis Investigative site

Glasgow, G12 OYN, United Kingdom
Novartis Investigative site

Liverpool, L7 8XP, United Kingdom
Novartis Investigative site

London, NW32QG, United Kingdom
Novartis Investigative site

London, SE1 9RT, United Kingdom
Novartis Investigative site

London, SE5 9RS, United Kingdom
Novartis Investigative site

London, W6 8RF, United Kingdom
Novartis Investigative site

Manchester, United Kingdom
Novartis Investigative site

Sheffield, S102SJ, United Kingdom
Oregon Health & Sciences University Hospital

Portland, Oregon, 97339, United States
The Ohio State University Wexner Medical Center

Portland, Ohio, 43210, United States
Virginia Mason in Seattle

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.